Internationally-Recognized Life Sciences Executive Joins the Advisory Board of Canadian Company Specializing in Biomedical Technologies for Obesity & Diabetes
VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 19, 2015) - M Pharmaceutical Inc. ("M Pharmaceutical" or the "Company") (CSE:MQ), is pleased to announced that Douglas Janzen of Vancouver - an established leader in the life sciences and biotechnology sectors with more than 20 years of leadership experience in corporate finance, business development and management - has been appointed Senior Clinical Advisor of the Company.
Janzen, the Co-Founder and Managing Director of Northview Ventures, and President and CEO of Aequus Pharmaceuticals, will immediately join the Advisory Board of M Pharmaceutical, a Canadian company committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life of people affected by obesity and diabetes.
"We are of course very pleased to have someone of Douglas's stature and background join us as Senior Clinical Advisor," said Dr. Martin Mintchev, President and Chief Executive Officer of M Pharmaceutical. "With his leadership reputation in biotechnology, pharma and life sciences and an impressive toolkit in the areas of entrepreneurship, finance and business development, Douglas is bound to deliver significant added value to everything we do in bringing our own innovative biomedical technologies to market."
Recognized for his passion for life sciences and biotechnology, Janzen serves on the boards of Neovasc, Aequus, Alabaster Technologies, Ico Therapeutics, Perimeter Medical Imaging, Renaissance Biosciences and Synaptive Technologies.
Before founding Northview Ventures, a strategic investment and consulting firm focused on life sciences and high tech, he served nine years as a senior executive at Cardiome Pharma, where he held the leadership positions of Chief Financial Officer (2003 - 2005), President and Chief Business Officer (2005 - 2009), and President and Chief Executive Officer (2009 - 2012).
At Cardiome, Janzen raised over $300 million from investors and completed over $1 billion in licensing deals. He formed the partnership with Merck that brought Cardiome's flagship product "Brinavess" through to clinical approval and marketing in Europe.
Prior to Cardiome, Janzen was an investment banker with Cormark Securities, acting as Managing Director of Life Sciences. He has completed over $1 billion in equity financing for Canadian bio-tech companies and has previously served as chair of LifeSciences BC and as a director with Biotech Canada. Janzen is also a former winner of Business in Vancouver's "Top 40 Under 40 Award".
About M Pharmaceutical Inc.
M Pharmaceutical Inc. is committed to developing and commercializing innovative biomedical technologies that improve the health and quality of life for people affected by obesity and diabetes. The Company currently has the exclusive rights to a family of biomedical technologies including (i) the eMosquito, for automatic and autonomous monitoring of blood glucose in diabetics; (ii) temporary controllable pseudobezoars, an innovative method for non-invasive dynamic gastric volume reduction for weight loss that has been recently tested in blind, placebo-controlled human studies; and (iii) gastrointestinal neurostimulators, using a laparoscopically-implantable technique for the treatment of obesity without permanent anatomical modification of the stomach. Commercial development of the eMosquito, the pseudobezoar and the neurostimulator technologies will require successful coordination and execution of a wide variety of technology disciplines.
FORWARD LOOKING STATEMENTS
This news release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the effect of the appointment of Mr. Janzen will have on the Company. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company's disclosure documents which can be found under the Company's profile on www.sedar.com and such factors as the Company failing to complete the commercialization of the eMosquito, the temporary pseudobezoars and the neurostimulator technologies.
FOR FURTHER INFORMATION PLEASE CONTACT: